Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul;21(3):283-294.
doi: 10.5217/ir.2023.00020. Epub 2023 Apr 20.

Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directions

Harris A Ahmad  1 , James E East  2 , Remo Panaccione  3 , Simon Travis  2 , James B Canavan  1 , Keith Usiskin  1 , Michael F Byrne  4   5
Affiliations
Review

Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directions

Harris A Ahmad et al. Intest Res. 2023 Jul.

Abstract

Inflammatory bowel disease encompasses Crohn's disease and ulcerative colitis and is characterized by uncontrolled, relapsing, and remitting course of inflammation in the gastrointestinal tract. Artificial intelligence represents a new era within the field of gastroenterology, and the amount of research surrounding artificial intelligence in patients with inflammatory bowel disease is on the rise. As clinical trial outcomes and treatment targets evolve in inflammatory bowel disease, artificial intelligence may prove as a valuable tool for providing accurate, consistent, and reproducible evaluations of endoscopic appearance and histologic activity, thereby optimizing the diagnosis process and identifying disease severity. Furthermore, as the applications of artificial intelligence for inflammatory bowel disease continue to expand, they may present an ideal opportunity for improving disease management by predicting treatment response to biologic therapies and for refining the standard of care by setting the basis for future treatment personalization and cost reduction. The purpose of this review is to provide an overview of the unmet needs in the management of inflammatory bowel disease in clinical practice and how artificial intelligence tools can address these gaps to transform patient care.

Keywords: Artificial intelligence; Endoscopy; Inflammatory bowel diseases.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Ahmad HA and Canavan J are employees of Bristol Myers Squibb.

East JE reports personal fees from Boston Scientific, Falk, Lumendi, Paion, and Satisfai, outside the submitted work. In addition, he has a patent Methods and framework for assessing image quality issued, and a patent Quantification of Barrett’s esophagus issued. Panaccione R reports personal fees from Abbott, AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, HC3 Communications, Janssen, Meducom, Merck, Mylan, Oppilan, Organon, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Receptos, Roche, Sandoz, Satisfai Health, Schering-Plough, Shire, Sublimity Therapeutics, Takeda Pharmaceuticals, Theravance Biopharma, Trellus Health, and UCB. Travis S has served as a paid consultant to AbbVie, Allergan, Amgen, Asahi, Bioclinica, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, ChemoCentryx, Cosmo, Enterome, Equillium, Ferring, GSK, Genentech, Genzyme, Giuliani SpA, Immunocore, Immunometabolism, Janssen, Lilly, MSD, Merck, Mestag, Neovacs, Novo Nordisk, NPS Pharmaceuticals, Pfizer, Proximagen, Receptos, Roche, Satisfai Health, Sensyne Health, Shire, Sigmoid Pharma, Sorriso, Takeda, Topivert, UCB, VHsquared, Vifor, and Zeria. He has received grants and/or has grants pending from AbbVie, ECCO, Helmsley Trust, IOIBD, Janssen, Lilly, Norman Collisson Foundation, Pfizer, UCB, UKIERI, and Vifor. He has received honoraria from AbbVie, Amgen, Biogen, Ferring, Lilly, Pfizer, and Takeda. He has had travel/accommodation expenses covered or reimbursed by AbbVie, Amgen, Biogen, Ferring, Lilly, JNJ, Pfizer, and Takeda. Usiskin K was an employee of Bristol Myers Squibb at the time of manuscript initiation. He reports personal fees from Arena, Bristol Myers Squibb, Crinetics Pharmaceuticals, Insmed, and Locust Walk Capital. Byrne MF is CEO and Founder of Satisfai Health.

Panaccione R and Travis S are editorial board members of the journal but were not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

Figures

Fig. 1.
Fig. 1.
Potential applications of artificial intelligence (AI) in inflammatory bowel disease diagnosis and management [3]. CD, Crohn’s disease; UC, ulcerative colitis.
Fig. 2.
Fig. 2.
Potential benefits of the application of artificial intelligence in inflammatory bowel disease clinical practice. CT, computed tomography; MR, magnetic resonance. Modified from Seyed Tabib NS, et al. Gut 2020;69:1520-1532 [10].
See this image and copyright information in PMC

References

    1. GBD 2017 Inflammatory Bowel Disease Collaborators The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30. - PMC - PubMed
    1. Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13:144–164. - PubMed
    1. Cohen-Mekelburg S, Berry S, Stidham RW, Zhu J, Waljee AK. Clinical applications of artificial intelligence and machine learning-based methods in inflammatory bowel disease. J Gastroenterol Hepatol. 2021;36:279–285. - PMC - PubMed
    1. Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn’s disease. Dis Mon. 2018;64:20–57. - PubMed
    1. Gajendran M, Loganathan P, Jimenez G, et al. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65:100851. - PubMed